managing egfr-resistant disease: t790 and beyond
Published 6 years ago • 116 plays • Length 20:27Download video MP4
Download video MP3
Similar videos
-
19:28
managing t790-positive egfr-mutated nsclc
-
21:09
mechanisms of resistance to egfr tki and new treatment strategies
-
20:07
acquired egfr resistance: what are the current therapeutic strategies?
-
13:06
managing t790-negative egfr-mutated nsclc
-
20:18
understanding, preventing, and delaying egfr resistance in the era of osimertinib
-
5:32
introduction to egfr inhibitors
-
1:04:03
hfpef series treatments
-
6:02
egfr mutation and cancer
-
16:56
colorectal cancer with acquired resistance to egfr antibodies: how to manage?
-
44:03
egfr: the challenge of primary and secondary resistance
-
20:35
tki-resistant egfr-mutant nsclc
-
24:36
treatment options for egfr t790m negative acquired resistance
-
20:24
targeted treatment with egfr tkis: front line options
-
21:35
long term management of egfr-mutant nsclc -tsao
-
17:27
how, when, and where to utilize erlotinib, afatinib, and gefitinib in egfr positive nsclc
-
23:10
egfr mutation positive tumors: treatment strategies in front line and at relapse
-
19:53
managing progression in egfr-mutant nsclc patients: potential impact of 2nd and 3rd generation tkis?
-
37:23
nsclc: integrating egfr-inhibiting therapies into clinical pathways for first-line treatment
-
18:06
egfr inhibitors in mutation ( ) patients: current therapeutic strategies in the frontline setting
-
3:00
egfr-resistant disease in lung cancer
-
29:24
gracecast-068_lung-cancer_sequist on acquired resistance to egfr
-
21:18
patient education and management of treatment expectation